Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy
复制标题
DOI：
10.2217/imt-2020-0211
复制
发表时间：
2020-09-16
期刊：
影响因子：
2.8
通讯作者：
Buti, Sebastiano
中科院分区：
文献类型：
--
作者：
Bersanelli, Melissa;Zielli, Teresa;Buti, Sebastiano
目的：评估接受免疫治疗的癌症患者中COVID-19的发生率和病程。患者和方法：我们报告了参加前瞻性观察性多中心INVIDIa-2研究的患者队列中诊断为COVID-19的流感样疾病事件帕尔马单中心。结果：在53名患者中，8名患者在2019/2020年流感季节期间出现流感样疾病，其中3人诊断为COVID-19。他们是男性，老年人，患有心血管疾病。在所有三例病例中均发现了COVID-19肺炎的放射学特征，尽管咽拭子仅在两例中呈阳性。结论：恶性肿瘤患者是严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染后发生严重事件的高危人群。
Aim:Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy.Patients & methods:We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the single center of Parma.Results:Among 53 patients, eight experienced influenza-like illness during the influenza season 2019/2020, and three of them had diagnosis of COVID-19. They were males, elderly, with cardiovascular disease. Radiological features of COVID-19 pneumonitis were found in all of three cases, although the pharyngeal swab resulted positive in only two. Two of these three patients died due to respiratory failure.Conclusion:Cancer patients are at high risk of severe events from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.